SLC5A2 and diabetic ketoacidosis: A systematic review andmeta-analysis of SGLT2 inhibitors CV outcome trials showed that the protectiveeffect was consistent across age categories, and elderly constituted about 50%of the total participants in the three major SGLT2 inhibitors trials [38, 39, 40].SGLT2 inhibitors use is safe in elderly patients, although they should be usedcautiously in patients with previous genitourinary infections, and in olderpatients with factors predisposing to diabetic ketoacidosis [29].